| Entry |
|
|---|
| Name |
Deuruxolitinib phosphate (USAN);
Leqselvi (TN) |
|---|
| Product |
|
|---|
| Formula |
C17H18N6. H3PO4
|
|---|
| Exact mass |
412.1864
|
|---|
| Mol weight |
404.36
|
|---|
| Structure |
|
|---|
| Class |
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG01642 CYP2C9 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Product (DG03114): | D11867<US> |
|
|---|
| Efficacy |
Hair regrowing agent, Janus kinase (JAK) inhibitor |
|---|
| Disease |
|
|---|
| Comment |
Treatment of alopecia areata
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04658 | Th1 and Th2 cell differentiation |
|
|---|
| Metabolism |
Enzyme: CYP2C9 [HSA: 1559]; CYP3A4 [HSA: 1576], CYP1A2 [HSA: 1544]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AF Janus-associated kinase (JAK) inhibitors
L04AF09 Deuruxolitinib
D11867 Deuruxolitinib phosphate (USAN) <US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
JAK Inhibitors
Deuruxolitinib
D11867 Deuruxolitinib phosphate (USAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
DG03114 Deuruxolitinib
D11867 Deuruxolitinib phosphate
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG03114 Deuruxolitinib
D11867 Deuruxolitinib phosphate
DG01642 CYP2C9 substrate
DG03114 Deuruxolitinib
D11867 Deuruxolitinib phosphate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03114 Deuruxolitinib
D11867 Deuruxolitinib phosphate
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
JAK family
JAK1
D11867 Deuruxolitinib phosphate (USAN) <US>
JAK2
D11867 Deuruxolitinib phosphate (USAN) <US>
TYK2
D11867 Deuruxolitinib phosphate (USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11867
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11867
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11867
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D11867
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
DG03114 Deuruxolitinib
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG03114 Deuruxolitinib
DG01642 CYP2C9 substrate
DG03114 Deuruxolitinib
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG03114 Deuruxolitinib
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 28
1 C8x C 15.5506 -11.5579
2 N5x N 15.5506 -12.9589
3 C8y C 16.7415 -13.6594
4 C8y C 18.0023 -12.9589
5 C8y C 18.0023 -11.5579
6 N5x N 16.7415 -10.8574
7 C8x C 19.3332 -13.3792
8 C8x C 20.1038 -12.2584
9 N4x N 19.3332 -11.1376
10 C8y C 16.7415 -15.0603
11 C8x C 15.6207 -15.9009
12 N4y N 16.0410 -17.2318
13 N5x N 17.4419 -17.2318
14 C8x C 17.9323 -15.9009
15 C1b C 13.6594 -17.2318
16 C1c C 14.8502 -17.9323
17 C1y C 14.8502 -19.3332
18 C3b C 13.6594 -15.8308
19 N3a N 13.6594 -14.4299
20 C1x C 13.7294 -20.1738
21 C1x C 14.1497 -21.5047
22 C1x C 15.5506 -21.5047
23 C1x C 15.9709 -20.1738
24 O1c O 20.8743 -16.6714
25 P1b P 22.2752 -16.6714
26 O1c O 23.6762 -16.6714
27 O1c O 22.2752 -15.2705
28 O1c O 22.2752 -18.0724
BOND 30
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 4 7 1
8 7 8 2
9 8 9 1
10 5 9 1
11 3 10 1
12 10 11 2
13 11 12 1
14 12 13 1
15 13 14 2
16 10 14 1
17 15 16 1
18 16 12 1
19 16 17 1 #Up
20 15 18 1
21 18 19 3
22 17 20 1
23 20 21 1
24 21 22 1
25 22 23 1
26 17 23 1
27 24 25 1
28 25 26 1
29 25 27 2
30 25 28 1
|
|---|
